JP2024512470A - Ｔ細胞調節ポリペプチド及びその使用方法 - Google Patents

Ｔ細胞調節ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP2024512470A
JP2024512470A JP2023556962A JP2023556962A JP2024512470A JP 2024512470 A JP2024512470 A JP 2024512470A JP 2023556962 A JP2023556962 A JP 2023556962A JP 2023556962 A JP2023556962 A JP 2023556962A JP 2024512470 A JP2024512470 A JP 2024512470A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
tmp
amino acid
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512470A5 (https=
Inventor
ザ サード ロナルド ディー． セイデル
ロドルフォ ジェイ． チャパーロ
ジョン エフ． ロス
サソ チェメルスキ
Original Assignee
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2024512470A publication Critical patent/JP2024512470A/ja
Publication of JP2024512470A5 publication Critical patent/JP2024512470A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2023556962A 2021-03-19 2022-03-17 Ｔ細胞調節ポリペプチド及びその使用方法 Pending JP2024512470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163270P 2021-03-19 2021-03-19
US63/163,270 2021-03-19
PCT/US2022/020819 WO2022197971A1 (en) 2021-03-19 2022-03-17 T-cell modulatory polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024512470A true JP2024512470A (ja) 2024-03-19
JP2024512470A5 JP2024512470A5 (https=) 2025-03-25

Family

ID=83320830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556962A Pending JP2024512470A (ja) 2021-03-19 2022-03-17 Ｔ細胞調節ポリペプチド及びその使用方法

Country Status (7)

Country Link
US (1) US20240067700A1 (https=)
EP (1) EP4308143A4 (https=)
JP (1) JP2024512470A (https=)
CN (1) CN116981470A (https=)
AU (1) AU2022238389A1 (https=)
CA (1) CA3212382A1 (https=)
WO (1) WO2022197971A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
WO2024264004A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2024264007A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
CN117024601A (zh) * 2023-07-14 2023-11-10 合肥工业大学 一种宣威火腿源抗氧化肽及其制备方法和活性测定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511949A (ja) * 2016-12-22 2020-04-23 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US20200172595A1 (en) * 2017-09-07 2020-06-04 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
WO2020205778A1 (en) * 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
WO2021172595A1 (ja) * 2020-02-28 2021-09-02 国立大学法人金沢大学 抗原提示細胞外小胞、それを含む組成物、及びそれらを製造するための方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511949A (ja) * 2016-12-22 2020-04-23 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US20200172595A1 (en) * 2017-09-07 2020-06-04 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
WO2020205778A1 (en) * 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MISHTO M. ET AL., FRONT IMMUNOL, vol. Vol. 10:2572, JPN6026000110, 2019, ISSN: 0005772376 *
WANG QJ. ET AL., CANCER IMMUNOL RES, vol. 4, JPN6026000111, 2016, pages 204 - 214, ISSN: 0005772377 *

Also Published As

Publication number Publication date
CA3212382A1 (en) 2022-09-22
CN116981470A (zh) 2023-10-31
AU2022238389A1 (en) 2023-10-05
WO2022197971A1 (en) 2022-09-22
EP4308143A1 (en) 2024-01-24
US20240067700A1 (en) 2024-02-29
EP4308143A4 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
US20250120996A1 (en) T-cell modulatory polypeptides and methods of use thereof
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP2024105296A (ja) Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質
JP7724254B2 (ja) バイアス型ｉｌ２ムテイン、方法、および組成物
JP7549579B2 (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
KR20220016945A (ko) 다중특이적 단백질
US20240368246A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230414777A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
US20240067699A1 (en) T-cell modulatory polypeptides and methods of use thereof
US20260109958A1 (en) T-Cell Modulatory Polypeptides and Methods of Use Thereof
EP4047021A1 (en) Ox40/pd-l1 bispecific antibody
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2024264004A2 (en) T-cell modulatory polypeptides and methods of use thereof
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260115